Nexalin Publishes Study on Neuroimaging Data Showing Brain-Network Effects and Clinical Improvement in Chronic Insomnia
Nexalin Technology, Inc. (NXL) announced a peer-reviewed study published in Psychotherapy and Psychosomatics, showing statistically significant improvement in sleep quality in patients treated with its DIFS™ technology. The study highlights brain-network modulation and validates Nexalin's non-pharmacologic treatment approach for mental health issues.
Topics: chronic insomnia clinical trial DIFS technology neuroimaging peer-reviewed study